Phase Ib/II Study of MEDI4736 evaluated in different combinations in Metastatic Pancreatic Ductal Carcinoma

Study identifier:D4198C00003

ClinicalTrials.gov identifier:NCT02583477

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Medical condition

Metastatic Pancreatic Ductal Adenocarcinoma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

MEDI4736 in combination with nab-paclitaxel and gemcitabine, MEDI4736 in combination with AZD5069

Sex

All

Actual enrollment

23

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 25 Mar 2016
Primary Completion Date: 09 Jul 2018
Study Completion Date: 09 Jul 2018

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria